US-based biopharmaceutical company Kezar Life Sciences has suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis. The decision to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback